Viscosupplementation - 5EU Analysis and Market Forecasts

Transcription

1 Viscosupplementation - 5EU Analysis and Market Forecasts

2 Viscosupplementation - 5EU Analysis and Market Forecasts BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or reportstore@bioportfolio.com 2

3 Viscosupplementation - 5EU Analysis and Market Forecasts Viscosupplementation - 5EU Analysis and Market Forecasts Summary Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability across the globe. Intra-articular viscosupplementation with hyaluronic acid (HA) has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade. Going forward, palliative pain treatments are likely to continue to fare well as healthcare reform kicks in and lag times for knee replacement become the norm. The increasing prevalence of OA and the lower cost of prescribing viscosupplementation compared with knee replacement surgery have prompted the medical community to take a closer look at this therapy. However, there is a growing concern among physicians that the updated American Academy of Orthopaedic Surgeons (AAOS) and Osteoarthritis Research Society International (OARSI) treatment guidelines for knee OA will result in increased insurance denials for viscosupplementation. Moving forward, industry consolidation and intense competition in the viscosupplementation arena will cause increasing numbers of companies to augment their research efforts to differentiate their products from the lower-end competitors. The motivation to incorporate the favorable properties of different agents into a more effective viscosupplementation product has led to the manipulation and development of next-generation HA formulations consisting of not only HAs, but also pharmaceuticals, such as corticosteroids. *This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase. Highlights Key Questions Answered - Future growth in the viscosupplementation market lies in the one-injection segment. What are the current adoption trends in different geographies? How will one-injection segment drive the market revenue growth in the upcoming years? - Reimbursement is the single greatest barrier to the market growth for viscosupplementation procedures. How does the current payer mix look like in different countries? - In recent years, there has been an expansion in the use of intra-articular HA viscosupplementation for treating OA at hips, shoulders, and other small joints. What are the current adoption trends in different regions? - Because the most prevalent treatment regimen varies from region to region, the competitive landscape in the viscosupplementation space can be quite different across the geographies covered in this report. Who are the leading players in the viscosupplementation market in different countries? Reasons to buy - What Do Physicians Think quotes provide a unique insight into how healthcare professionals are reacting to 3

4 events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information. Additional Details Publisher : Global Data Reference : GDME1151CFR Number of Pages : 0 Report Format : PDF Publisher Information : 4

5 Table Of Contents for Viscosupplementation - 5EU Analysis and Market Forecasts 1 Table of Contents1.1 List of Tables1.2 List of Figures2 Introduction2.1 Catalyst2.2 Related Reports3 Treatment Modalities Overview3.1 Treatment Paradigm3.1.1 Physical Therapies3.1.2 Medications3.1.3 Hyaluronic Acid Viscosupplementation3.1.4 Surgical Intervention4 Industry Overview4.1 Procedural Trends4.2 Market Access4.3 Reimbursement4.4 Mergers and Acquisitions/Key Partnerships4.4.1 Meda AB Acquires Rottapharm Medaus for $3.1 Billion (October 2014)4.4.2 Founders of Anteis Establish Aptissen (March 2014)4.4.3 Bioventus Acquires Durolane Assets from Galderma (February 2014)4.4.4 Zimmer to Combine with Biomet in a Transaction Valued at $13.35 Billion (April 2014)4.4.5 Johnson & Johnson Acquires Synthes for $19.7 Billion (June 2012)5 Market Drivers, Opportunities, and Barriers5.1 Driver: Rising Prevalence of OA5.2 Driver: Multimodal Treatment Paradigm for OA5.3 Driver: Viscosupplementation Delays Total Knee Replacement5.4 Driver: Side Effects of NSAIDs, Corticosteroids, and Narcotics5.5 Driver: Direct-To-Consumer Marketing5.6 Opportunity: Expanding Indications5.7 Opportunity: New-Generation HA Derivatives5.8 Opportunity: Increased Use After Arthroscopic Surgeries5.9 Opportunity: Self-Pay Market5.10 Opportunity: Emerging Countries5.11 Barrier: Unfavorable Reimbursement Scenario5.12 Barrier: Pricing Erosion5.13 Barrier: Cost-Effective Pharmacological Therapies5.14 Barrier: Will The Rising Popularity of PRP Injection Impact the Viscosupplementation Market?5.15 Barrier: Cost-Conscious Patients in Emerging Countries6 Unmet Needs6.1 Lack of Consensus on Clinical Efficacy of Viscosupplementation in Knee OA6.2 Insufficient Evidence to Prove the Clinical Efficacy of Viscosupplementation in Other Joints6.3 Better Understanding of the Basic Science6.4 Ultrasound-Guided Injection7 Competitive Assessment7.1 Major Viscosupplementation Products7.1.1 Adant7.1.2 Arthrum7.1.3 Curavisc7.1.4 Durolane7.1.5 Euflexxa7.1.6 Fermathron7.1.7 Gel-One7.1.8 Go-On7.1.9 Hyalgan Hyalubrix and HyalOne Jonexa NeoVisc Orthovisc and Monovisc Ostenil Recosyn RenehaVis Supartz/ARTZ Suplasyn Synocrom Synolis V-A Synovial Synvisc and Synvisc-One7.2 Other Viscosupplementation Products8 Pipeline Products8.1 Overview8.2 Gel-Syn (IBSA Institut Biochimique S.A.)8.3 Cingal (Anika Therapeutics)8.4 Hydros-TA (Carbylan Therapeutics)8.5 Additional Indication for Synvisc-One (Sanofi)8.6 Hymovis (Fidia Farmaceutici S.p.A.)8.7 HA-NSAID Conjugates (Seikagaku Corporation)8.8 Additional Indication for Supartz/ARTZ (Seikagaku Corporation)8.9 Clodronate-HA Conjugates (Abiogen Pharma)9 Current and Future Players9.1 Trends in Corporate Strategy9.2 Major Manufacturers9.2.1 Anika Therapeutics9.2.2 Ferring Pharmaceuticals9.2.3 Fidia Farmaceutici S.p.A Meda AB9.2.5 Sanofi9.2.6 Seikagaku Corporation9.3 Major Marketing Partners9.3.1 Bioventus9.3.2 DePuy Synthes9.3.3 Zimmer-Biomet10 Market Outlook10.1 Market Share Analysis by Country10.2 By Market Segment One-Injection Segment Three-Injection Segment Five-Injection Segment10.3 By Geography Overview France Germany Italy Spain UK11 Appendix11.1 Bibliography11.2 Abbreviations11.3 Report Methodology Overview Coverage Secondary Research Forecasting Methodology Primary Research Key Opinion Leader Interviews Expert Panel Validation11.4 Physicians and Specialists Included in This Study11.5 About the Authors Analysts Jim Coutcher, MS, Global Head of Healthcare11.6 About MediPoint11.7 About GlobalData11.8 Contact Us11.9 Disclaimer 5

6 List Of Tables in Viscosupplementation - 5EU Analysis and Market Forecasts 1.1 List of Tables Table 1: 5EU Procedure Trends for Viscosupplementation, by Joint Type, Table 2: 5EU Procedure Trends for Viscosupplementation, by Treatment Regimen, Table 3: Differences Between US FDA Approval and EU CE Marking of Medical Devices Table 4: Potential Clinical Benefits of HA-NSAIDs Conjugates Table 5: Current CPGs on the Use of Viscosupplementation in Joints Other Than the Knee Table 6: Product Profile - Adant Table 7: Product Profile - Arthrum Table 8: Product Profile - Curavisc Table 9: Product Profile - Durolane Table 10: Product Profile - Euflexxa Table 11: Product Profile - Fermathron Table 12: Product Profile - Gel-One Table 13: Product Profile - Go-On Table 14: Product Profile - Hyalgan Table 15: Product Profile - Hyalubrix and HyalOne Table 16: Product Profile - Jonexa Table 17: Product Profile - NeoVisc Table 18: Product Profile - Orthovisc and Monovisc Table 19: Product Profile - Ostenil Table 20: Product Profile - Recosyn Table 21: Product Profile - RenehaVis Table 22: Product Profile - Supartz/ARTZ Table 23: Product Profile - Suplasyn Table 24: Product Profile - Synocrom Table 25: Product Profile - Synolis V-A Table 26: Product Profile - Synovial Table 27: Product Profile - Synvisc and Synvisc-One 6

7 Table 28: Other Viscosupplementation Products in the 5EU Market, 2015 Table 29: Major Pipeline Products in the Viscosupplementation Market, 2015 Table 30: Company Profile - Anika Therapeutics Table 31: Anika Therapeutics Viscosupplementation Portfolio Assessment, 2015 Table 32: SWOT Analysis - Anika Therapeutics Table 33: Company Profile - Ferring Pharmaceuticals Table 34: Ferring Pharmaceutical s Viscosupplementation Portfolio Assessment, 2015 Table 35: SWOT Analysis - Ferring Pharmaceuticals Table 36: Company Profile - Fidia Farmaceutici S.p.A. Table 37: Fidia Farmaceutici S.p.A. s Viscosupplementation Portfolio Assessment, 2015 Table 38: SWOT Analysis - Fidia Farmaceutici S.p.A. Table 39: Company Profile - Meda AB Table 40: Meda AB s Viscosupplementation Portfolio Assessment, 2015 Table 41: SWOT Analysis - Meda AB Table 42: Company Profile - Sanofi Table 43: Sanofi s Viscosupplementation Portfolio Assessment, 2015 Table 44: SWOT Analysis - Sanofi Table 45: Company Profile - Seikagaku Corporation Table 46: Seikagaku Corporation s Viscosupplementation Portfolio Assessment, 2015 Table 47: SWOT Analysis - Seikagaku Corporation Table 48: Company Profile - Bioventus Table 49: Bioventus Viscosupplementation Portfolio Assessment, 2015 Table 50: SWOT Analysis - Bioventus Table 51: Company Profile - DePuy Synthes Table 52: DePuy Synthes Viscosupplementation Portfolio Assessment, 2015 Table 53: SWOT Analysis - DePuy Synthes Table 54: Company Profile - Zimmer-Biomet Table 55: Zimmer-Biomet s Viscosupplementation Portfolio Assessment, 2015 Table 56: SWOT Analysis - Zimmer-Biomet Table 57: 5EU Viscosupplementation One-Injection Market Revenue ($m), by Region, Table 58: 5EU Viscosupplementation Three-Injection Market Revenue ($m), by Region,

8 Table 59: 5EU Viscosupplementation Five-Injection Market Revenue ($m), by Region, Table 60: 5EU Viscosupplementation Market Revenue ($m), by Segment, Table 61: 5EU Viscosupplementation Market Revenue ($m), by Geography, Table 62: France Viscosupplementation Market Revenue ($m), Table 63: Germany Viscosupplementation Market Revenue ($m), Table 64: Italy Viscosupplementation Market Revenue ($m), Table 65: Spain Viscosupplementation Market Revenue ($m), Table 66: UK Viscosupplementation Market Revenue ($m),

9 List Of Figures, Charts and Diagrams in Viscosupplementation - 5EU Analysis and Market Forecasts 1.2 List of Figures Figure 1: 5EU Procedure Trends for Viscosupplementation, by Joint Type, 2014 Figure 2: 5EU Adoption Trends for Viscosupplementation, by Treatment Regimen, 2014 Figure 3: 5EU Procedure Trends for Viscosupplementation, by Treatment Regimen, Figure 4: Payer Mix for Viscosupplementation in France, 2014 Figure 5: Payer Mix for Viscosupplementation in Germany, 2014 Figure 6: Payer Mix for Viscosupplementation in Italy, 2014 Figure 7: Payer Mix for Viscosupplementation in Spain, 2014 Figure 8: Payer Mix for Viscosupplementation in the UK, 2014 Figure 9: France Viscosupplementation Market Share, by Product, 2014 Figure 10: Germany Viscosupplementation Market Share, by Product, 2014 Figure 11: Italy Viscosupplementation Market Share, by Product, 2014 Figure 12: Spain Viscosupplementation Market Share, by Product, 2014 Figure 13: UK Viscosupplementation Market Share, by Product, 2014 Figure 14: 5EU Viscosupplementation One-Injection Market Revenue ($m), by Region, Figure 15: 5EU Viscosupplementation Three-Injection Market Revenue ($m), by Region, Figure 16: 5EU Viscosupplementation Five-Injection Market Revenue ($m), by Region, Figure 17: 5EU Viscosupplementation Market Revenue ($m), by Segment, Figure 18: 5EU Viscosupplementation Market Revenue ($m), by Segment, 2014 and 2021 Figure 19: 5EU Viscosupplementation Market Revenue ($m), by Geography, 2014 and 2021 Figure 20: France Viscosupplementation Market Revenue ($m), Figure 21: France Viscosupplementation Market Revenue Distribution, 2014 and 2021 Figure 22: Germany Viscosupplementation Market Revenue ($m), Figure 23: Germany Viscosupplementation Market Revenue Distribution, 2014 and 2021 Figure 24: Italy Viscosupplementation Market Revenue ($m), Figure 25: Italy Viscosupplementation Market Revenue Distribution, 2014 and 2021 Figure 26: Spain Viscosupplementation Market Revenue ($m),

10 Figure 27: Spain Viscosupplementation Market Revenue Distribution, 2014 and 2021 Figure 28: UK Viscosupplementation Market Revenue ($m), Figure 29: UK Viscosupplementation Market Revenue Distribution, 2014 and 2021 Figure 30: Breakdown of Physician Survey Participants by Geography (N=61) Figure 31: Breakdown of Other Primary Research Participants by Geography (N=50) 10

11 How to Buy... Viscosupplementation - 5EU Analysis and Market Forecasts Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $4450 Single User Price $8900 Site License Price $11645 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 11